Moody's Corporation vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Moody's Corporation trades at $464 (market cap $79.44B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.95 (market cap $25.27B). The key difference: Moody's Corporation is far larger — about 3.1× Royalty Pharma plc Class A Ordinary Shares's market cap, and Royalty Pharma plc Class A Ordinary Shares pays the higher dividend (1.66%). Which is the better fit depends on your goals — on Pluang, investors hold Moody's Corporation for 132 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| MCO | RPRX | |
|---|---|---|
Market Cap | $79.44B | $25.27B |
Volume | 526,684 | 3,671,183 |
Sector | Financials | Health |
52-Week High | $539.61 | $63.96 |
52-Week Low | $412.23 | $35.44 |
Typical Hold Time | 132 Days | 1 Days |
Enterprise Value | $85.46B | $32.50B |
Dividend Yield | 0.9% | 1.66% |
Signals from Pluang's Aura AI — not financial advice
Moody's Corporation (MCO) trades at $462.10, up 2.77% with strong earnings momentum after beating Q2 2026 EPS estimates. The stock shows robust fundamentals with 34.25% net margins and 80.15% ROE, though technical indicators signal near-term bearish pressure. Recent strategic moves include expanding Asia-Pacific presence through a PhilRatings stake and new credit risk product launches.
Outlook remains positive given consistent earnings beats and analyst consensus target of $536.40 (16% upside). Key risks include high valuation multiples (P/E 29.1) and potential macroeconomic sensitivity affecting credit rating demand. Institutional sentiment leans bullish with 56% buy ratings supporting long-term growth thesis.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →